GSK Establishes Oncology Consortium With An Eye On Combinations
This article was originally published in The Pink Sheet Daily
The company has aligned with six leading cancer centers to study investigational cancer drugs, with the ambition of advancing novel combinations, including both targeted therapies and immunotherapies.
You may also be interested in...
At a time when $10,000-per-month pricing is the norm in oncology, GSK has priced its just-approved BRAF inhibitor Tafinlar at $7,600, on the lower end by today’s standards. Company says it is planning to file the combination of Tafinlar with Mekinist – also just approved by FDA – in a matter of weeks in the U.S.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.